{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:29:32Z","timestamp":1791646172202,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jtha.2023.10.020","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:30:36Z","timestamp":1698784236000},"page":"594-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Between a rock and a hard place: resumption of oral anticoagulant therapy after intracranial hemorrhage"],"prefix":"10.1016","volume":"22","author":[{"given":"Brian T.","family":"Grainger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"McFadyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.10.020_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hest.2020.01.001","article-title":"Anticoagulant-associated intracerebral hemorrhage","volume":"1","author":"Morotti","year":"2020","journal-title":"Brain Hemorrhages"},{"key":"10.1016\/j.jtha.2023.10.020_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.thromres.2017.11.001","article-title":"Warfarin resumption following anticoagulant-associated intracranial hemorrhage: a systematic review and meta-analysis","volume":"160","author":"Chai-Adisaksopha","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.10.020_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0268-960X(98)90028-5","article-title":"Management of oral anticoagulant-induced intracranial haemorrhage","volume":"12","author":"Butler","year":"1998","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2023.10.020_bib4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.thromres.2013.10.024","article-title":"Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes","volume":"132","author":"Witt","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.10.020_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","article-title":"Death and disability from warfarin-associated intracranial and extracranial hemorrhages","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2023.10.020_bib6","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.STR.26.8.1471","article-title":"Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses","volume":"26","author":"Hart","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.10.020_bib7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinte.164.8.880","article-title":"The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage","volume":"164","author":"Rosand","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2023.10.020_bib8","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.wneu.2015.06.033","article-title":"Analysis of venous thromboembolism risk in patients undergoing craniotomy","volume":"84","author":"Algattas","year":"2015","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jtha.2023.10.020_bib9","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1093\/neuros\/nyy333","article-title":"Venous thromboembolism in patients with spontaneous intracerebral hemorrhage: a multicenter study","volume":"84","author":"Ding","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jtha.2023.10.020_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ana.25079","article-title":"Oral anticoagulation and functional outcome after intracerebral hemorrhage","volume":"82","author":"Biffi","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtha.2023.10.020_bib11","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2013-306476","article-title":"Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis","volume":"85","author":"Poon","year":"2014","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jtha.2023.10.020_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.0000000000004235","article-title":"Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation","volume":"89","author":"Korompoki","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jtha.2023.10.020_bib13","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","article-title":"Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis","volume":"48","author":"Murthy","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.10.020_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019672","article-title":"Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis","volume":"8","author":"Zhou","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2023.10.020_bib15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S1474-4422(21)00264-7","article-title":"Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2023.10.020_bib16","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"American Heart Association\/American Stroke Association. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.10.020_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2023.10.020_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/NRL.0b013e3181a93bac","article-title":"Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage","volume":"15","author":"Orken","year":"2009","journal-title":"Neurologist"},{"key":"10.1016\/j.jtha.2023.10.020_bib19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1212\/01.wnl.0000208408.98482.99","article-title":"Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage","volume":"66","author":"Davis","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jtha.2023.10.020_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000330643","article-title":"German Stroke Study Collaboration. Recurrent stroke after lobar and deep intracerebral hemorrhage: a hospital-based cohort study","volume":"32","author":"Weimar","year":"2011","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jtha.2023.10.020_bib21","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2010.03882.x","article-title":"Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk","volume":"8","author":"Hawryluk","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.020_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1747493019828555","article-title":"Management of oral anticoagulation after intracerebral hemorrhage","volume":"14","author":"Kuramatsu","year":"2019","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jtha.2023.10.020_bib23","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage","volume":"41","author":"Majeed","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.10.020_bib24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/STROKEAHA.116.014643","article-title":"Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation","volume":"48","author":"Pennlert","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.10.020_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/00015458.2005.11679715","article-title":"Risk analysis of thrombo-embolic and recurrent bleeding events in the management of intracranial haemorrhage due to oral anticoagulation","volume":"105","author":"De Vleeschouwer","year":"2005","journal-title":"Acta Chir Belg"},{"key":"10.1016\/j.jtha.2023.10.020_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12883-021-02126-7","article-title":"How do you manage ANTICOagulant therapy in neurosurgery? The ANTICO survey of the Italian Society of Neurosurgery (SINCH)","volume":"21","author":"Prior","year":"2021","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jtha.2023.10.020_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.07.008","article-title":"Resumption of direct oral anticoagulants in patients with acute spontaneous intracerebral hemorrhage","volume":"28","author":"Kato","year":"2019","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jtha.2023.10.020_bib28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7861\/clinmedicine.18-4-314","article-title":"The reversal of anticoagulation in clinical practice","volume":"18","author":"Thomas","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jtha.2023.10.020_bib29","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1212\/WNL.0000000000004704","article-title":"Brain microbleeds, anticoagulation, and hemorrhage risk: meta-analysis in stroke patients with AF","volume":"89","author":"Charidimou","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jtha.2023.10.020_bib30","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/jnnp-2016-314697","article-title":"The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice","volume":"88","author":"Banerjee","year":"2017","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jtha.2023.10.020_bib31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ana.410410607","article-title":"High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy","volume":"41","author":"Nicoll","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtha.2023.10.020_bib32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/02688697.2013.812184","article-title":"Recommencement of anticoagulation in chronic subdural haematoma: a systematic review and meta-analysis","volume":"28","author":"Chari","year":"2014","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.jtha.2023.10.020_bib33","doi-asserted-by":"crossref","first-page":"e792","DOI":"10.1016\/j.wneu.2017.10.091","article-title":"Resumption of antithrombotic agents in chronic subdural hematoma: a systematic review and meta-analysis","volume":"109","author":"Phan","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jtha.2023.10.020_bib34","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.wneu.2021.02.135","article-title":"Timing of restarting anticoagulation and antiplatelet therapies after traumatic subdural hematoma\u2014a\u00a0single institution experience","volume":"150","author":"Naylor","year":"2021","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jtha.2023.10.020_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/jamainternmed.2016.9369","article-title":"Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation","volume":"177","author":"Nielsen","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2023.10.020_bib36","article-title":"Safest time to resume oral anticoagulation in patients with traumatic brain injury","volume":"10","author":"Puckett","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.jtha.2023.10.020_bib37","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.10.020_bib38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.10.020_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11940-017-0477-y","article-title":"Resumption of anticoagulation after intracranial hemorrhage","volume":"19","author":"da Silva","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.jtha.2023.10.020_bib40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejim.2020.05.020","article-title":"Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs","volume":"80","author":"Poli","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jtha.2023.10.020_bib41","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1474-4422(21)00298-2","article-title":"Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial","volume":"20","author":"Schreuder","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2023.10.020_bib42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.amjcard.2021.09.011","article-title":"Risk of intracranial hemorrhage caused by direct oral anticoagulants for stroke prevention in patients with atrial fibrillation (from a network meta-analysis of randomized controlled trials)","volume":"162","author":"Lv","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2023.10.020_bib43","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaneurol.2018.2215","article-title":"Association of intracranial hemorrhage risk with non-vitamin K antagonist oral anticoagulant use vs aspirin use: a systematic review and meta-analysis","volume":"75","author":"Huang","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtha.2023.10.020_bib44","article-title":"Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approach","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2023.10.020_bib45","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2023.10.020_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/tsaco-2020-000605","article-title":"Restarting and timing of oral anticoagulation after traumatic intracranial hemorrhage: a review and summary of ongoing and planned prospective randomized clinical trials","volume":"5","author":"King","year":"2020","journal-title":"Trauma Surg Acute Care Open"},{"key":"10.1016\/j.jtha.2023.10.020_bib47","first-page":"149","article-title":"Prothrombin complex concentrates: an update","volume":"8","author":"Franchini","year":"2010","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jtha.2023.10.020_bib48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/rth2.12089","article-title":"Pharmacological reversal of the direct oral anticoagulants\u2014a comprehensive review of the literature","volume":"2","author":"Shaw","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.020_bib49","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet\u00a0alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.10.020_bib50","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1055\/a-1400-6159","article-title":"ANNEXA-4 Investigators. Restart of anticoagulant therapy and risk of thrombosis, rebleeding, and death after factor Xa inhibitor reversal in major bleeding patients","volume":"121","author":"Milling","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.020_bib51","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0022-5223(95)70309-8","article-title":"Long-term results of valve replacement with the St. Jude Medical prosthesis","volume":"109","author":"Baudet","year":"1995","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtha.2023.10.020_bib52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","article-title":"Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses","volume":"89","author":"Cannegieter","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.10.020_bib53","doi-asserted-by":"crossref","first-page":"457S","DOI":"10.1378\/chest.126.3_suppl.457S","article-title":"Antithrombotic therapy in valvular heart disease\u2014native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Salem","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2023.10.020_bib54","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ncl.2014.12.005","article-title":"Antiplatelet and anticoagulant therapy after intracerebral hemorrhage","volume":"33","author":"Zazulia","year":"2015","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jtha.2023.10.020_bib55","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jacc.2003.09.064","article-title":"Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative monocentric study of 680 patients","volume":"43","author":"Laplace","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2023.10.020_bib56","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jacc.2007.10.058","article-title":"Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications","volume":"51","author":"Russo","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2023.10.020_bib57","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/archneur.57.12.1710","article-title":"Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk","volume":"57","author":"Phan","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jtha.2023.10.020_bib58","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/icvts\/ivs545","article-title":"When should you restart anticoagulation in patients who suffer an intracranial bleed who also have a prosthetic valve?","volume":"16","author":"Chandra","year":"2013","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.jtha.2023.10.020_bib59","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/eurheartj\/ehy056","article-title":"Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves","volume":"39","author":"Kuramatsu","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2023.10.020_bib60","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0025-6196(11)60970-1","article-title":"Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion","volume":"82","author":"Aguilar","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtha.2023.10.020_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102711","article-title":"Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials","volume":"20","author":"Dufrost","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2023.10.020_bib62","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/jth.14936","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: a systematic review and meta-analysis","volume":"18","author":"Ortel","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.020_bib63","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/CIRCULATIONAHA.109.906347","article-title":"Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A","volume":"121","author":"Lijfering","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.10.020_bib64","first-page":"695","article-title":"The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S","volume":"91","author":"De Stefano","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.10.020_bib65","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.18239","article-title":"Thrombophilia testing: a British Society for Haematology guideline","volume":"198","author":"Arachchillage","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.10.020_bib66","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S0049-3848(16)30100-1","article-title":"Intracranial hemorrhage in cancer patients treated with anticoagulation","volume":"140","author":"Weinstock","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.10.020_bib67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jth.14336","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors","volume":"17","author":"Carney","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.020_bib68","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/rth2.12377","article-title":"Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism","volume":"4","author":"Carney","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.020_bib69","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/j.jacc.2020.08.089","article-title":"Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials","volume":"76","author":"Turagam","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2023.10.020_bib70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-17-00201","article-title":"Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study","volume":"13","author":"Nielsen-Kudsk","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jtha.2023.10.020_bib71","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial","volume":"312","author":"Reddy","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2023.10.020_bib72","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnis.2010.004564","article-title":"Long-term safety and effectiveness of inferior vena cava filters in patients with stroke","volume":"3","author":"Somarouthu","year":"2011","journal-title":"J\u00a0Neurointerv Surg"},{"key":"10.1016\/j.jtha.2023.10.020_bib73","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1941874420907531","article-title":"Use and removal of inferior vena cava filters in patients with acute brain injury","volume":"10","author":"Melmed","year":"2020","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.jtha.2023.10.020_bib74","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11739-019-02077-5","article-title":"Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism","volume":"14","author":"Mellado","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jtha.2023.10.020_bib75","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12959-021-00345-z","article-title":"Patients with venous thromboembolism after spontaneous intracerebral hemorrhage: a review","volume":"19","author":"Cai","year":"2021","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2023.10.020_bib76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jth.15126","article-title":"New anticoagulants: moving beyond the direct oral anticoagulants","volume":"19","author":"Fredenburgh","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.020_bib77","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.020_bib78","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.10.020_bib79","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI inhibitors in early clinical trials: a meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.020_bib80","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"Pacific AMI Investigators. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.10.020_bib81","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.10.020_bib82","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2023.10.020_bib83","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1001\/archinte.160.22.3431","article-title":"Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy","volume":"160","author":"Douketis","year":"2000","journal-title":"Arch Intern Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:40:28Z","timestamp":1761536428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623007900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1538783623007900"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.10.020","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Between a rock and a hard place: resumption of oral anticoagulant therapy after intracranial hemorrhage","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}